PROTOCOL ACTIVATION

 

NRG-GY014: “A Phase II Study of Tazemetostat (EPZ-6438) (IND #138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma” NCI Version Date: 01/25/2019

 

 

Documents are posted on CTSU

 

 

Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address